Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Healthtrust
US Department of Justice
Johnson and Johnson
Daiichi Sankyo
Dow
Moodys
Argus Health
Harvard Business School

Generated: May 23, 2018

DrugPatentWatch Database Preview

Depomed Inc Company Profile

« Back to Dashboard

Summary for Depomed Inc
International Patents:321
US Patents:26
Tradenames:6
Ingredients:4
NDAs:7
Patent Litigation for Depomed Inc: See patent lawsuits for Depomed Inc

Drugs and US Patents for Depomed Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Depomed Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-004 Aug 25, 2011 RX Yes No 8,536,130 ➤ Try a Free Trial ➤ Try a Free Trial
Depomed Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-004 Aug 25, 2011 RX Yes No RE39593 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Depomed Inc CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes 8,927,604 ➤ Try a Free Trial ➤ Try a Free Trial
Depomed Inc NUCYNTA tapentadol hydrochloride TABLET;ORAL 022304-002 Nov 20, 2008 RX Yes No RE39593 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Depomed Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Depomed Inc PROQUIN XR ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021744-001 May 19, 2005 6,340,475 ➤ Try a Free Trial
Depomed Inc NUCYNTA tapentadol hydrochloride TABLET;ORAL 022304-003 Nov 20, 2008 6,071,970 ➤ Try a Free Trial
Depomed Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-005 Aug 25, 2011 6,071,970 ➤ Try a Free Trial
Depomed Inc CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 6,974,595 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for DEPOMED INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Potassium Oral Solution (Sachet) 50 mg ➤ Subscribe 2011-01-24
➤ Subscribe Capsules 25 mg ➤ Subscribe 2012-11-14
➤ Subscribe Extended-release Tablets 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg ➤ Subscribe 2012-11-20
➤ Subscribe Oral Solution 20 mg/mL ➤ Subscribe 2013-12-20
➤ Subscribe Tablets 300 mg and 600 mg ➤ Subscribe 2011-10-31
➤ Subscribe Tablets x50 mg, 75 mg, and 100 mg ➤ Subscribe 2012-11-20
➤ Subscribe Oral Solution 20 mg/mL ➤ Subscribe 2013-12-30

Non-Orange Book US Patents for Depomed Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,114,384 Process for the production of an abuse-proofed solid dosage form ➤ Try a Free Trial
8,475,813 Methods of treatment using a gastric retained gabapentin dosage ➤ Try a Free Trial
8,231,905 Gastric retained gabapentin dosage form ➤ Try a Free Trial
7,612,112 Methods of treatment using a gastric retained gabapentin dosage ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Depomed Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
11/010 Ireland ➤ Try a Free Trial PRODUCT NAME: TAPENTADOL IN BASIC FORM OR IN THE FORM OF A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY TAPENTADOL HYDROCHLORIDE; NAT REGISTRATION NO/DATE: PA1189/007/001-008 20101221; FIRST REGISTRATION NO/DATE: PA1189/008/001-008 21/12/2010 GERMANY 75043.00.00 75044.00.00 75045.00.00 19/08/2010 GERMANY 76261.00.00 76262.00.00 76263.00.00 76264.00.00 76265.00.00 19/08/2010 GERMANY 75046.00.00 75047.00.00 75048.00.00 19/08/2010 GERMANY 76266.00.00 76267.00.00 76268.00.0076269.00.00 76270.00.00 20100819
90004-0.L Sweden ➤ Try a Free Trial PRODUCT NAME: TAPENTADOL; NAT. REG. NO/DATE: 42622-42628 20100910; FIRST REG.: DE 7543-7548,7661-76270" EESGODKLANDKOD="DE" EESGODKDATUM="2010-08-19" SEGODKNR="42622-42628 20100819
0693475/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: TAPENTADOL; REGISTRATION NO/DATE: SWISSMEDIC 60530 20110222
793 Luxembourg ➤ Try a Free Trial 91793, EXPIRES: 20200712
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
Cantor Fitzgerald
Fuji
Accenture
Cerilliant
QuintilesIMS
Dow
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.